Keywords: Nycomed, Forest Labs, Daxas, FDA complete response letter, NDA, COPD

Further delay in US approval for Forest Labs/Nycomed’s Daxas, but no additional clinical trials requested by FDA

Article | 18 May 2010

Print This

There was disappointment for independent Swiss drugmaker Nycomed and its US partner Forest Laboratories yesterday, after the US Food and ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in